GLG News by Hematologists (US)

Proteolix's selective proteosome inhibitor PR-171 have shown pre-clinical activity in slid tumor animal models, but only a small Phase Ib clinical trial of 14 patients have been completed. based on spectrum of activity of a similar compound ( Valcade, Mellinium), the main efficacy of this agent...

" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.

Low cost generics to be produced in China will lower drug costs.

As world economies improve more money will be spent globally on cancer care expanding potential markets

The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.

National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?

The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.

Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...

That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!

"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."